Literature DB >> 18787630

Diagnostic utility of P63 and CD10 in distinguishing cutaneous spindle cell/sarcomatoid squamous cell carcinomas and atypical fibroxanthomas.

Jordan M Hall1, Jeff S Saenger, Oluwole Fadare.   

Abstract

The pathologic distinction of atypical fibroxanthomas (AFXs) from cutaneous spindle cell/sarcomatoid squamous cell carcinomas (SCSCCs) may occasionally pose a significant diagnostic challenge, given the substantial clinicopathologic overlap between these lesions. Recent studies indicate that p63 and CD10 are expressed in significant proportions of SCSCC and AFX, respectively. The purpose of this study is to investigate the utility of CD10 and p63 in distinguishing cutaneous SCSCCs and AFXs. The immunohistochemical expression of p63, CD10, cytokeratin AE-1/3, cytokeratin 5/6 and a cytokeratin cocktail (Kermix) was evaluated in an archived group of 23 AFXs and 10 SCSCCs. CD10 was positive in 18/23 AFXs (78%), with most demonstrating strong and/or diffuse staining. Three of 23 AFXs (13%), all negative for cytokeratins, showed focal and weak nuclear staining for p63. Two of 23 AFXs (9%) demonstrated very focal or weak staining for only one cytokeratin; in both cases, p63 and CD10 were negative. One AFX was negative with all immunostains. CD10 was positive in 6/10 SCSCCs (60%), with half demonstrating strong and/or diffuse staining. P63 was positive in 9/10 SCSCCs (90%), with most demonstrating strong and diffuse staining. One SCSCC was negative for p63, but positive with two cytokeratin immunostains. In conclusion, the expression of any of the cytokeratins evaluated herein significantly distinguished AFX from SCSCC. CD10 used in isolation, however, was not useful in making this distinction (positive in 18/23 AFXs versus 6/10 SCSCCs, p=0.4). The addition of CD10 to a panel that includes p63 did not provide any additional information to that obtained from the latter alone. Overall, the most effective combination to distinguish AFX from SCSCC was p63 and cytokeratin AE-1/3. Positivity for both p63 and cytokeratin AE-1/3 was seen in 9/10 SCSCCs (90%) and was not observed in any of the 23 AFXs (p<0.0001). The usefulness of CD10 in this differential diagnosis is limited.

Entities:  

Keywords:  Atypical fibroxanthoma; CD10; p63; sarcomatoid/spindle cell squamous cell carcinoma; skin

Year:  2008        PMID: 18787630      PMCID: PMC2480581     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  21 in total

1.  Diagnosis: atypical fibroxanthoma or not? Evaluating spindle cell malignancies on sun damaged skin: a practical approach.

Authors:  P W Heintz; C R White
Journal:  Semin Cutan Med Surg       Date:  1999-03

2.  CD10, a useful marker for atypical fibroxanthomas.

Authors:  David Weedon; Richard Williamson; Basit Mirza
Journal:  Am J Dermatopathol       Date:  2005-04       Impact factor: 1.533

3.  Two cases of cytokeratin positivity in atypical fibroxanthoma.

Authors:  Cheryl Bansal; Prasanna Sinkre; David Stewart; Clay J Cockerell
Journal:  J Clin Pathol       Date:  2007-05-04       Impact factor: 3.411

4.  p63 is a useful marker for cutaneous spindle cell squamous cell carcinoma.

Authors:  Jorge E Dotto; Earl J Glusac
Journal:  J Cutan Pathol       Date:  2006-06       Impact factor: 1.587

5.  The utility of cytokeratin 5/6 in the recognition of cutaneous spindle cell squamous cell carcinoma.

Authors:  J E Sigel; M Skacel; W F Bergfeld; N S House; M S Rabkin; J R Goldblum
Journal:  J Cutan Pathol       Date:  2001-11       Impact factor: 1.587

6.  Metastasizing atypical fibroxanthoma (cutaneous malignant histiocytoma): report of five cases.

Authors:  Jennifer Z Cooper; Scott R Newman; Glynis A Scott; Marc D Brown
Journal:  Dermatol Surg       Date:  2005-02       Impact factor: 3.398

7.  Atypical fibroxanthoma: a clinicopathological study of 89 cases.

Authors:  Basit Mirza; David Weedon
Journal:  Australas J Dermatol       Date:  2005-11       Impact factor: 2.875

8.  Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1.

Authors:  James S Lewis; Jon H Ritter; Samir El-Mofty
Journal:  Mod Pathol       Date:  2005-11       Impact factor: 7.842

Review 9.  Localized cutaneous metastases from an atypical fibroxanthoma.

Authors:  T J Giuffrida; Chris J Kligora; Glenn D Goldstein
Journal:  Dermatol Surg       Date:  2004-12       Impact factor: 3.398

Review 10.  Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part one.

Authors:  David S Cassarino; Damian P Derienzo; Ronald J Barr
Journal:  J Cutan Pathol       Date:  2006-03       Impact factor: 1.587

View more
  8 in total

1.  Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.

Authors:  Justin A Bishop; Elizabeth A Montgomery; William H Westra
Journal:  Am J Surg Pathol       Date:  2014-02       Impact factor: 6.394

2.  Primary cutaneous osteosarcoma of the scalp.

Authors:  Yusra Al-Janabi; Khalid Al-Janabi; Kallirroi Tzafetta; Mahir Petkar
Journal:  BMJ Case Rep       Date:  2018-05-18

3.  A case of painful centrofacial nodule with discharging sinuses and blackish nasal discharge.

Authors:  Saumya Panda
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

4.  Mouse genetic background influences whether HrasG12V expression plus Cdkn2a knockdown causes angiosarcoma or undifferentiated pleomorphic sarcoma.

Authors:  Laura P Brandt; Joachim Albers; Tomas Hejhal; Svende Pfundstein; Ana Filipa Gonçalves; Antonella Catalano; Peter J Wild; Ian J Frew
Journal:  Oncotarget       Date:  2018-04-13

Review 5.  p63 Is a Promising Marker in the Diagnosis of Unusual Skin Cancer.

Authors:  Artem Smirnov; Lucia Anemona; Flavia Novelli; Cristina M Piro; Margherita Annicchiarico-Petruzzelli; Gerry Melino; Eleonora Candi
Journal:  Int J Mol Sci       Date:  2019-11-17       Impact factor: 5.923

Review 6.  Role of immunohistochemistry in the diagnosis and staging of cutaneous squamous-cell carcinomas (Review).

Authors:  Elena Bălășescu; Andreea-Cristina Gheorghe; Andreea Moroianu; Gabriela Turcu; Alice Brînzea; Mihaela Antohe; Anastasia Hodorogea; Lorena Manea; Mihaela Balaban; Răzvan Andrei; Ionela Hulea; Cristiana Gabriela Popp; Luciana Nichita; Mirela Daniela Cioplea; Sabina Andrada Zurac; Daniela Adriana Ion; Roxana Ioana Nedelcu
Journal:  Exp Ther Med       Date:  2022-04-11       Impact factor: 2.447

Review 7.  Diagnostic Immunohistochemistry in Cutaneous Neoplasia: An Update.

Authors:  Leigh A Compton; George F Murphy; Christine G Lian
Journal:  Dermatopathology (Basel)       Date:  2015-04-08

8.  Atypical fibroxanthoma/pleomorphic dermal sarcoma of the scalp with aberrant expression of HMB-45: a pitfall in dermatopathology.

Authors:  Viviana Piras; Caterina Ferreli; Laura Atzori; Giampietro Pinna; Luca Pilloni
Journal:  Pathologica       Date:  2020-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.